Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 19/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3949287 | 1.00 | CHRM5 (0.57) | CHRM5ALDH1A1ALDH2 | |
| SCHEMBL950201 | 0.79 | ALDH1A1 (0.69) | CHRM5ALDH1A1ALDH2 | |
| SCHEMBL950200 | 0.79 | ALDH1A1 (0.69) | CHRM5ALDH1A1ALDH2 | |
| SCHEMBL18955215 | 0.77 | CHRM5 (0.67) | CHRM5 | |
| SCHEMBL13781378 | 0.75 | CHRM5 (0.35) | CHRM5 | |
| SCHEMBL953500 | 0.73 | ALDH1A1 (0.60) | CHRM5ALDH1A1ALDH2 | |
| SCHEMBL953499 | 0.73 | ALDH1A1 (0.60) | CHRM5ALDH1A1ALDH2 | |
| SCHEMBL5426542 | 0.73 | CHRM5 (0.88) | CHRM5 | |
| SCHEMBL23764661 | 0.70 | CHRM5 (0.67) | CHRM5 | |
| SCHEMBL18955129 | 0.70 | CHRM5 (0.67) | CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| EP-2013216-A2 | NOVEL SPIRO [IMIDAZOLIDINE-4, 3' -INDOLE] 2, 2', 5' (1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007091946-A1 | USE OF SPIRO [ IMIDAZOLIDINE-4, 3'-INDOLE] 2, 2', 5' (1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007091948-A2 | NOVEL SPIRO [IMIDAZOLIDINE-4, 3´-INDOLE] 2, 2´,5´(1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007091948-A2 | NOVEL SPIRO [IMIDAZOLIDINE-4, 3´-INDOLE] 2, 2´,5´(1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV2, TRPV3 | CHRM5 507/4885ALDH1A1 502/4885ALDH2 1126/4885 |
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV5, TRPV2 | CHRM5 356/4885ALDH1A1 550/4885ALDH2 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.